Fig. 1From: Tazemetostat decreases β-catenin and CD13 protein expression in HEPG-2 and Hepatitis B virus-transfected HEPG-2 with decreased cell viabilityMTT cell viability assay of HEPG2 cells after 48 h incubation with 1 nM, 2 nM, 0.5 μM, 1 μM, 4 μM and 6 μM concentrations of Taz versus DMSO control; (***): P < 0.001Back to article page